Compare AMP & HLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AMP | HLN |
|---|---|---|
| Founded | 1894 | 2022 |
| Country | United States | United Kingdom |
| Employees | N/A | 24524 |
| Industry | Investment Managers | Package Goods/Cosmetics |
| Sector | Finance | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.4B | 41.1B |
| IPO Year | 2009 | N/A |
| Metric | AMP | HLN |
|---|---|---|
| Price | $453.62 | $9.31 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 1 |
| Target Price | ★ $544.91 | N/A |
| AVG Volume (30 Days) | 545.2K | ★ 9.0M |
| Earning Date | 04-23-2026 | 02-26-2026 |
| Dividend Yield | 1.43% | ★ 1.94% |
| EPS Growth | ★ 9.77 | N/A |
| EPS | ★ 9.68 | N/A |
| Revenue | ★ $18,911,000,000.00 | N/A |
| Revenue This Year | $1.79 | $6.55 |
| Revenue Next Year | $4.20 | $4.42 |
| P/E Ratio | ★ $46.36 | $49.05 |
| Revenue Growth | ★ 5.49 | N/A |
| 52 Week Low | $422.37 | $8.71 |
| 52 Week High | $550.18 | $11.42 |
| Indicator | AMP | HLN |
|---|---|---|
| Relative Strength Index (RSI) | 41.94 | 48.64 |
| Support Level | $450.43 | $9.30 |
| Resistance Level | $457.58 | $9.50 |
| Average True Range (ATR) | 10.57 | 0.14 |
| MACD | -2.51 | 0.05 |
| Stochastic Oscillator | 34.81 | 88.30 |
Ameriprise Financial has evolved into a diversified financial services provider that generates roughly 65% of its operating profit from advice and wealth management. With nearly $1.2 trillion in segment assets under management and advisory at year-end 2025, and with roughly 10,600 affiliated and employee advisors, Ameriprise is one of the larger US-based wealth managers. It also boasts a reasonably large asset management franchise in Columbia Threadneedle, which boasted $678 billion in assets under management at year-end 2025. The firm's third segment is its retirement and protection services business, which sells insurance products to the firm's advisory clients. After eliminations, Ameriprise had $1.69 trillion in assets under management and advisory across segments at year-end 2025.
Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.